Pivotal roles of GM-CSF in autoimmunity and inflammation

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Shiomi, Aoi ^a   Usui, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 17; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CEREBROSPINAL FLUID; DENDRITIC CELL; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CROHN DISEASE; HYPERSENSITIVITY; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; PHYSIOLOGY; PULMONARY ALVEOLAR PROTEINOSIS;

ANIMALS; AUTOIMMUNITY; CROHN DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY; INFLAMMATION; LUNG DISEASES, INTERSTITIAL; PULMONARY ALVEOLAR PROTEINOSIS;

EID: 84925624378     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/568543     Document Type: Review

References (174)

1. A. W. Burgess, J. Camakaris, and D. Metcalf, "Purification and properties of colony stimulating factor from mouse lung conditioned medium,"The Journal of Biological Chemistry, vol. 252, no. 6, pp. 1998-2003, 1977.
2. J. A. Hamilton and A. Achuthan, "Colony stimulating factors and myeloid cell biology in health and disease," Trends in Immunology, vol. 34, no. 2, pp. 81-89, 2013.
3. M. El-Behi, B. Ciric, H. Dai et al., "The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF," Nature Immunology, vol. 12, no. 6, pp. 568-575, 2011.
4. L. Codarri, G. Gyülvészii, V. Tosevski et al., "RORγ3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation," Nature Immunology, vol. 12, no. 6, pp. 560-567, 2011.
5. J. A. Hamilton, "GM-CSF in inflammation and autoimmunity," Trends in Immunology, vol. 23, no. 8, pp. 403-408, 2002.
6. A. J. Fleetwood, A. D. Cook, and J. A. Hamilton, "Functions of granulocyte-macrophage colony-stimulating factor," Critical Reviews in Immunology, vol. 25, no. 5, pp. 405-428, 2005.
7. H. Fukuzawa, M. Sawada, T. Kayahara et al., "Identification of GM-CSF in Paneth cells using single-cell RT-PCR," Biochemical and Biophysical Research Communications, vol. 312, no. 4, pp. 897-902, 2003.
8. J. R. Lukens, M. J. Barr, D. D. Chaplin, H. Chi, and T.- D. Kanneganti, "Inflammasome-derived IL-1beta regulates the production of GM-CSF by CD4(+) T cells and gammadelta T cells," Journal of Immunology, vol. 188, no. 7, pp. 3107-3115, 2012.
9. T. Duhen and D. J. Campbell, "IL-1β promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes," The Journal of Immunology, vol. 193, no. 1, pp. 120-129, 2014.
10. H. Quill, A. Gaur, and R. P. Phipps, "Prostaglandin E2- dependent induction of granulocyte-macrophage colonystimulating factor secretion by cloned murine helper T cells," Journal of Immunology, vol. 142, no. 3, pp. 813-818, 1989.
11. C. Shang, J. Attema, D. Cakouros, P. N. Cockerill, and M. F. Shannon, "Nuclear factor of activated T cells contributes to the function of the CD28 response region of the granulocyte macrophage-colony stimulating factor promoter," International Immunology, vol. 11, no. 12, pp. 1945-1956, 1999.
12. B. V. Johnson, A. G. Bert, G. R. Ryan, A. Condina, and P. N. Cockerill, "Granulocyte-macrophage colony-stimulating factor enhancer activation requires cooperation between NFAT and AP-1 elements and is associated with extensive nucleosome reorganization," Molecular and Cellular Biology, vol. 24, no. 18, pp. 7914-7930, 2004.
13. H. Ozawa, S. Aiba, S. Nakagawa, and H. Tagami, "Interferongamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression," European Journal of Immunology, vol. 26, no. 3, pp. 648-652, 1996.
14. J. H. Jansen, G. H. M. Wientjens, W. E. Fibbe, R. Willemze, and H. C. Kluin-Nelemans, "Inhibition of human macrophage colony formation by interleukin 4,"The Journal of Experimental Medicine, vol. 170, no. 2, pp. 577-582, 1989.
15. K. Sagawa, M. Mochizuki, S. Sugita, K. Nagai, T. Sudo, and K. Itoh, "Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction," Cytokine, vol. 8, pp. 501-506, 1996.
16. A. Tsuboi, E. S. Masuda, Y. Naito, H. Tokumitsu, K.-I. Arai, and N. Arai, "Calcineurin potentiates activation of the granulocytemacrophage colony-stimulating factor gene in T cells: involvement of the conserved lymphokine element 0," Molecular Biology of the Cell, vol. 5, no. 1, pp. 119-128, 1994.
17. S. M. Hatfield and N. W. Roehm, "Cyclosporine and FK506 inhibition of murine mast cell cytokine production," Journal of Pharmacology and Experimental Therapeutics, vol. 260, no. 2, pp. 680-688, 1992.
18. I. M. Adcock and G. Caramori, "Cross-talk between proinflammatory transcription factors and glucocorticoids," Immunology and Cell Biology, vol. 79, no. 4, pp. 376-384, 2001.
19. F. Colotta, F. Bussolino, N. Polentarutti et al., "Differential expression of the common β and specific α chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells," Experimental Cell Research, vol. 206, no. 2, pp. 311-317, 1993.
20. M. Roasa, S. Gordon, and P. R. Taylor, "Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice," European Journal of Immunology, vol. 37, no. 9, pp. 2518-2528, 2007.
21. M. Martinez-Moczygemba and D. P. Huston, "Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GMCSF," Journal of Allergy and Clinical Immunology, vol. 112, no. 4, pp. 653-666, 2003.
22. G. Hansen, T. R. Hercus, B. J. McClure et al., "The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation," Cell, vol. 134, no. 3, pp. 496-507, 2008.
23. M. A. Guthridge, E. F. Barry, F. A. Felquer et al., "The phosphoserine-585-dependent pathway of the GM-CSF/IL- 3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-κB and induction of bcl-2," Blood, vol. 103, no. 3, pp. 820-827, 2004.
24. P.-Y. Berclaz, B. Carey, M.-D. Fillipi et al., "GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS," American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 1, pp. 114-121, 2007.
25. T.R. Hercus, U. Dhagat, W. L.T. Kan et al., "Signalling by the βc family of cytokines," Cytokine and Growth Factor Reviews, vol. 24, no. 3, pp. 189-201, 2013.
26. M. A. Guthridge, J. A. Powell, E. F. Barry et al., "Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch," The EMBO Journal, vol. 25, no. 3, pp. 479-489, 2006.
27. J. A. Hamilton, "Colony-stimulating factors in inflammation and autoimmunity," Nature Reviews Immunology, vol. 8, no. 7, pp. 533-544, 2008.
28. E. Stanley, G. J. Lieschke, D. Grail et al., "Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 12, pp. 5592-5596, 1994.
29. A. J. Fleetwood, T. Lawrence, J. A. Hamilton, and A. D. Cook, "Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation," Journal of Immunology, vol. 178, no. 8, pp. 5245-5252, 2007.
30. P. J. Morrissey, L. Bressler, L. S. Park, A. Alpert, and S. Gillis, "Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells," Journal of Immunology, vol. 139, no. 4, pp. 1113-1119, 1987.
31. J. M. Alvaro-Garcia, N. J. Zvaifler, and G. S. Firestein, "Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis," The Journal of Experimental Medicine, vol. 170, no. 3, pp. 865-875, 1989.
32. Y. Shibata, P.-Y. Berclaz, Z. C. Chroneos, M. Yoshida, J. A. Whitsett, and B. C. Trapnell, "GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1," Immunity, vol. 15, no. 4, pp. 557-567, 2001.
33. P.-Y. Berclaz, Y. Shibata, J. A. Whitsett, and B. C. Trapnell, "GMCSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ-mediatedmolecular connection between innate and adaptive immunity in the lung," Blood, vol. 100, no. 12, pp. 4193-4200, 2002.
34. P.-Y. Berclaz, Z. Zsengellér, Y. Shibata et al., "Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1," Journal of Immunology, vol. 169, no. 11, pp. 6332-6342, 2002.
35. A. D. Cook, E. L. Braine, and J. A. Hamilton, "Stimulusdependent requirement for granulocyte-macrophage colonystimulating factor in inflammation," Journal of Immunology, vol. 173, no. 7, pp. 4643-4651, 2004.
36. T. Sakagami, K. Uchida, T. Suzuki et al., "Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis," The New England Journal of Medicine, vol. 361, no. 27, pp. 2679-2681, 2009.
37. J. Gomez-Cambronero, J. Horn, C. C. Paul, and M. A. Baumann, "Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway," Journal of Immunology, vol. 171, no. 12, pp. 6846-6855, 2003.
38. D. Metcalf, "Hematopoietic cytokines," Blood, vol. 111, no. 2, pp. 485-491, 2008.
39. R. Paine III, A. M. Preston, S. Wilcoxen et al., "Granulocytemacrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice," The Journal of Immunology, vol. 164, no. 5, pp. 2602-2609, 2000.
40. A. M. LeVine, J. A. Reed, K. E. Kurak, E. Cianciolo, and J. A. Whitsett, "GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection," Journal of Clinical Investigation, vol. 103, no. 4, pp. 563-569, 1999.
41. J. F. Seymour, G. J. Lieschke, D. Grail, C. Quilici, G. Hodgson, and A. R. Dunn, "Mice lacking both granulocyte colonystimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis. Lung disease, amyloidosis, and reduced long-term survival," Blood, vol. 90, no. 8, pp. 3037-3049, 1997.
42. Y. Hirata, L. Egea, S. M. Dann, L. Eckmann, and M. F. Kagnoff, "GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen," Cell Host and Microbe, vol. 7, no. 2, pp. 151-163, 2010.
43. C. H. Serezani, S. Kane, L. Collins, M. Morato-Marques, J. J. Osterholzer, and M. Peters-Golden, "Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis," Journal of Immunology, vol. 189, no. 2, pp. 906-915, 2012.
44. H. L. Collins and G. J. Bancroft, "Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans," European Journal of Immunology, vol. 22, no. 6, pp. 1447-1454, 1992.
45. B. Parajuli, Y. Sonobe, J. Kawanokuchi et al., "GM-CSFincreases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia," Journal of Neuroinflammation, vol. 9, article 268, 2012.
46. C. A. Sorgi, S. Rose, N. Court et al., "GM-CSF priming drives bone marrow-derived macrophages to a pro-inflammatory pattern and downmodulates PGE2 in response to TLR2 ligands," PLoS ONE, vol. 7, no. 7, Article ID e40523, 2012.
47. T. Krausgruber, K. Blazek, T. Smallie et al., "IRF5 promotes inflammatory macrophage polarization and T H1-TH17 responses," Nature Immunology, vol. 12, no. 3, pp. 231-238, 2011.
48. F. A. W. Verreck, T. De Boer, D. M. L. Langenberg et al., "Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4560-4565, 2004.
49. D. Zhou, C. Huang, Z. Lin et al., "Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways," Cellular Signalling, vol. 26, no. 2, pp. 192-197, 2014.
50. I. L. King, M. A. Kroenke, and B. M. Segal, "GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role inTh effector cell differentiation after subcutaneous immunization," Journal of Experimental Medicine, vol. 207, no. 5, pp. 953-961, 2010.
51. E. Daro, B. Pulendran, K. Brasel et al., "Polyethylene glycolmodified GM-CSF expands CD11bhighCD11chigh but not CD11blowCD11chigh murine dendritic cells in vivo: a comparative analysis with Flt3 ligand," The Journal of Immunology, vol. 165, no. 1, pp. 49-58, 2000.
52. C. Caux, B. Vanbervliet, C. Massacrier et al., "CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα," Journal of Experimental Medicine, vol. 184, no. 2, pp. 695-706, 1996.
53. Y. Zhan, E. M. Carrington, A. van Nieuwenhuijze et al., "GM-CSF increases cross-presentation and CD103 expression by mouse CD8+ spleen dendritic cells," European Journal of Immunology, vol. 41, no. 9, pp. 2585-2595, 2011.
54. I. K. Campbell, A. van Nieuwenhuijze, E. Segura et al., "Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells," Journal of Immunology, vol. 186, no. 9, pp. 5468-5477, 2011.
55. M. Greter, J. Helft, A. Chow et al., "GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells," Immunity, vol. 36, no. 6, pp. 1031-1046, 2012.
56. Y. Zhan, Y. Xu, and A. M. Lew, "The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor," Molecular Immunology, vol. 52, no. 1, pp. 30-37, 2012.
57. I. Sonderegger, G. Iezzi, R. Maier, N. Schmitz, M. Kurrer, and M. Kopf, "GM-CSF mediates autoimmunity by enhancing IL- 6-dependent Th17 cell development and survival," Journal of Experimental Medicine, vol. 205, no. 10, pp. 2281-2294, 2008.
58. K. Uchida, D. C. Beck, T. Yamamoto et al., "GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis,"The New England Journal of Medicine, vol. 356, no. 6, pp. 567-579, 2007.
59. P. J. Rauch, A. Chudnovskiy, C. S. Robbins et al., "Innate response activator B cells protect against microbial sepsis," Science, vol. 335, no. 6068, pp. 597-601, 2012.
60. G. F. Weber, B. G. Chousterman, I. Hilgendorf et al., "Pleural innate response activator B cells protect against pneumonia via aGM-CSF-IgMaxis,"The Journal of ExperimentalMedicine, vol. 211, no. 6, pp. 1243-1256, 2014.
61. C. M. Snapper, M. A. Moorman, F. R. Rosas, M. R. Kehry, C. R. Maliszewski, and J. J. Mond, "IL-3 and granulocyte-macrophage colony-stimulating factor strongly induce Ig secretion by sortpurified murine B cell activated through the membrane Ig, but not the CD40, signaling pathway," Journal of Immunology, vol. 154, no. 11, pp. 5842-5850, 1995.
62. W. Sheng, F. Yang, Y. Zhou et al., "STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation," Cell Research, vol. 24, no. 12, pp. 1387-1402, 2014.
63. A. Shiomi, T. Usui, Y. Ishikawa, M. Shimizu, K. Murakami, and T. Mimori, "GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKGmice,"The Journal of Immunology, vol. 193, no. 2, pp. 849-859, 2014.
64. R. Noster, R. Riedel, M.-F. Mashreghi et al., "IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells," Science TranslationalMedicine, vol. 6, Article ID 241ra80, 2014.
65. M. J. McGeachy, "GM-CSF: the secret weapon in the TH17 arsenal," Nature Immunology, vol. 12, no. 6, pp. 521-522, 2011.
66. D. J. Cousins, T. H. Lee, and D. Z. Staynov, "Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression ofTh2 cytokines," Journal of Immunology, vol. 169, no. 5, pp. 2498-2506, 2002.
67. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins,"TheJournal of Immunology, vol. 136, no. 7, pp. 2348-2357, 1986.
68. Y. Komiyama, S. Nakae, T. Matsuki et al., "IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis," Journal of Immunology, vol. 177, no. 1, pp. 566-573, 2006.
69. H. H. Hofstetter, S. M. Ibrahim, D. Koczan et al., "Therapeutic efficacy of IL-17 neutralization inmurine experimental autoimmune encephalomyelitis," Cellular Immunology, vol. 237, no. 2, pp. 123-130, 2005.
70. S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, "Suppression of immune induction of collagen-induced arthritis in IL-17- deficient mice," Journal of Immunology, vol. 171, no. 11, pp. 6173-6177, 2003.
71. H. Kellner, "Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential," Therapeutic Advances inMusculoskeletal Disease, vol. 5, no. 3, pp. 141-152, 2013.
72. W. B. van den Berg and I. B. McInnes, "Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics," Seminars in Arthritis and Rheumatism, vol. 43, no. 2, pp. 158-170, 2013.
73. M. Kleinewietfeld and D. A. Hafler, "The plasticity of human Treg and Th17 cells and its role in autoimmunity," Seminars in Immunology, vol. 25, no. 4, pp. 305-312, 2013.
74. E. V. Acosta-Rodriguez, L. Rivino, J. Geginat et al., "Surface phenotype and antigenic specificity of human interleukin 17- producing T helper memory cells," Nature Immunology, vol. 8, no. 6, pp. 639-646, 2007.
75. K. Ghoreschi, A. Laurence, X.-P. Yang et al., "Generation of pathogenic TH17 cells in the absence of TGF-β signalling," Nature, vol. 467, no. 7318, pp. 967-971, 2010.
76. L. Cosmi, R. Cimaz, L. Maggi et al., "Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis," Arthritis and Rheumatism, vol. 63, no. 8, pp. 2504-2515, 2011.
77. A. Peters, Y. Lee, and V. K. Kuchroo, "The many faces of Th17 cells," Current Opinion in Immunology, vol. 23, no. 6, pp. 702-706, 2011.
78. F. Annunziato, L. Cosmi, V. Santarlasci et al., "Phenotypic and functional features of human Th17 cells," The Journal of Experimental Medicine, vol. 204, no. 8, pp. 1849-1861, 2007.
79. L. Maggi, V. Santarlasci, M. Capone et al., "CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC," European Journal of Immunology, vol. 40, no. 8, pp. 2174-2181, 2010.
80. L. Cosmi, R. De Palma, V. Santarlasci et al., "Human interleukin 17-producing cells originate froma CD161+ CD4+ T cell precursor," Journal of ExperimentalMedicine, vol. 205, no. 8, pp. 1903-1916, 2008.
81. C. Piper, A. M. Pesenacker, D. Bending et al., "Brief report: T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity," Arthritis & Rheumatology, vol. 66, no. 7, pp. 1955-1960, 2014.
82. H. Kebir, I. Ifergan, J. I. Alvarez et al., "Preferential recruitment of interferon-γ-expressing TH17 cells in multiple sclerosis," Annals of Neurology, vol. 66, no. 3, pp. 390-402, 2009.
83. K. Hirota, J. H. Duarte, M. Veldhoen et al., "Fate mapping of IL-17-producing T cells in inflammatory responses," Nature Immunology, vol. 12, no. 3, pp. 255-263, 2011.
84. J. R. Lukens, M. J. Barr, D. D. Chaplin, H. Chi, and T.-D. Kanneganti, "Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4+ T cells and γδ T cells," Journal of Immunology, vol. 188, no. 7, pp. 3107-3115, 2012.
85. C. E. Zielinski, F. Mele, D. Aschenbrenner et al., "Pathogeninduced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β," Nature, vol. 484, no. 7395, pp. 514-518, 2012.
86. R. I. Mazzucchelli, A. Riva, and S. K. Durum, "The human IL-7 receptor gene: deletions, polymorphisms and mutations," Seminars in Immunology, vol. 24, no. 3, pp. 225-230, 2012.
87. S. M. Churchman and F. Ponchel, "Interleukin-7 in rheumatoid arthritis," Rheumatology, vol. 47, no. 6, pp. 753-759, 2008.
88. H. Brühl, J. Cihak, M. Niedermeier et al., "Important role of interleukin-3 in the early phase of collagen-induced arthritis," Arthritis & Rheumatism, vol. 60, no. 5, pp. 1352-1361, 2009.
89. C. Chavany, C. Vicario-Abejón, G. Miller, and M. Jendoubi, "Transgenic mice for interleukin 3 develop motor neuron degeneration associated with autoimmune reaction against spinal cord motor neurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 19, pp. 11354-11359, 1998.
90. R. Yamada, T. Tanaka, M. Unoki et al., "Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, andmaximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease," American Journal ofHumanGenetics, vol. 68, no. 3, pp.674-685, 2001.
91. Y. Nakamura, P. Christodoulopoulos, L. Cameronet al., "Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge,"TheJournal of Allergy and Clinical Immunology, vol. 105, no. 6, part 1, pp. 1146-1152, 2000.
92. H. Park, Z. Li, X. O. Yang et al., "A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17," Nature Immunology, vol. 6, no. 11, pp. 1133-1141, 2005.
93. S. Haak, A. L. Croxford, K. Kreymborg et al., "IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice,"The Journal of Clinical Investigation, vol. 119, no. 1, pp. 61-69, 2009.
94. J. L. McQualter, R. Darwiche, C. Ewing et al., "Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis," Journal of Experimental Medicine, vol. 194, no. 7, pp. 873-881, 2001.
95. E.D. Ponomarev, L. P. Shriver, K. Maresz, J. Pedras-Vasconcelos, D. Verthelyi, and B. N. Dittel, "GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis," Journal of Immunology, vol. 178, no. 1, pp. 39-48, 2007.
96. O. Perrella, P. B. Carrieri, R. de Mercato, and G. A. Buscaino, "Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis," European Neurology, vol. 33, no. 2, pp. 152-155, 1993.
97. P. B. Carrieri, V. Provitera, T. de Rosa, G. Tartaglia, F. Gorga, and O. Perrella, "Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity," Immunopharmacology and Immunotoxicology, vol. 20, no. 3, pp. 373-382, 1998.
98. H. G. Fischer, A. K. Bielinsky, B. Nitzgen, W. Däubener, and U. Hadding, "Functional dichotomy of mouse microglia developed in vitro: differential effects of macrophage and granulocyte/macrophage colony-stimulating factor on cytokine secretion and antitoxoplasmic activity," Journal of Neuroimmunology, vol. 45, no. 1-2, pp. 193-201, 1993.
99. H. González, D. Elgueta, A. Montoya, and R. Pacheco, "Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases," Journal of Neuroimmunology, vol. 274, no. 1-2, pp. 1-13, 2014.
100. L. Qian, K. S. Tan, S.-J. Wei et al., "Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptorindependent reduction of NADPH oxidase activity," Journal of Immunology, vol. 179, no. 2, pp. 1198-1209, 2007.
101. C. C. Ferrari, M. C. Pott Godoy, R. Tarelli, M. Chertoff, A. M. Depino, and F. J. Pitossi, "Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra," Neurobiology of Disease, vol. 24, no. 1, pp. 183-193, 2006.
102. R. Gordon, V. Anantharam, and A. G. Kanthasamy, "Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation," Journal of Neuroinflammation, vol. 9, article 82, 2012.
103. H. González and R. Pacheco, "T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases," Journal of Neuroinflammation, vol. 11, no. 1, article 201, 2014.
104. I. L. King, T. L. Dickendesher, and B. M. Segal, "Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease," Blood, vol. 113, no. 14, pp. 3190-3197, 2009.
105. B. Aube, S. A. Levesque, A. Pare et al., "Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases," The Journal of Immunology, vol. 193, no. 5, pp. 2438-2454, 2014.
106. M. Ahn, W. Yang, H. Kim, J.-K. Jin, C. Moon, and T. Shin, "Immunohistochemical study of arginase-1 in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis," Brain Research, vol. 1453, pp. 77-86, 2012.
107. M. J. Carson, J. M. Doose, B. Melchior, C. D. Schmid, and C. C. Ploix, "CNS immune privilege: hiding in plain sight," Immunological Reviews, vol. 213, no. 1, pp. 48-65, 2006.
108. A. Schottelius, "Therole of GM-CSF inmultiple sclerosis," Drug Research (Stuttg), vol. 63, supplement 1, article S8, 2013.
109. A. L. Cornish, I. K. Campbell, B. S. McKenzie, S. Chatfield, and I. P. Wicks, "G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis," Nature Reviews Rheumatology, vol. 5, no. 10, pp. 554-559, 2009.
110. D. Mulherin, O. Fitzgerald, and B. Bresnihan, "Synovial tissue macrophage populations and articular damage in rheumatoid arthritis," Arthritis and Rheumatism, vol. 39, no. 1, pp. 115-124, 1996.
111. W. D. Xu, G. S. Firestein, R. Taetle, K. Kaushansky, and N. J. Zvaifler, "Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions,"The Journal of Clinical Investigation, vol. 83, no. 3, pp. 876-882, 1989.
112. C. Fiehn, M. Wermann, A. Pezzutto, M. Hufner, and B. Heilig, "GM-CSF plasma concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy," Zeitschrift für Rheumatologie, vol. 51, no. 3, pp. 121-126, 1992.
113. B. P. C. Hazenberg, M. A. van Leeuwen, M. H. van Rijswijk, A. C. Stern, and E. Vellenga, "Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colonystimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis," Blood, vol. 74, no. 8, pp. 2769-2770, 1989.
114. M. Gattorno, P. Facchetti, F. Ghiotto et al., "Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype," Clinical & Experimental Immunology, vol. 109, no. 1, pp. 4-11, 1997.
115. T. Leizer, J. Cebon, J. E. Layton, and J. A. Hamilton, "Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction ofGM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor," Blood, vol. 76, no. 10, pp. 1989-1996, 1990.
116. I.K. Campbell, U. Novak, J. Cebon, J. E. Layton, and J. A. Hamilton, "Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1,"The Journal of Immunology, vol. 147, no. 4, pp. 1238-1246, 1991.
117. I. K. Campbell, M. J. Rich, R. J. Bischof, A. R. Dunn, D. Grail, and J. A. Hamilton, "Protection fromcollagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice," Journal of Immunology, vol. 161, no. 7, pp. 3639-3644, 1998.
118. A. D. Cook, E. L. Braine, I. K. Campbell, M. J. Rich, and J. A. Hamilton, "Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease," Arthritis Research, vol. 3, no. 5, pp. 293-298, 2001.
119. I. K. Campbell, A. Bendele, D. A. Smith, and J. A. Hamilton, "Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice," Annals of the Rheumatic Diseases, vol. 56, no. 6, pp. 364-368, 1997.
120. M. Hashimoto, K. Hirota, H. Yoshitomi et al., "Complement drives Th17 cell differentiation and triggers autoimmune arthritis," The Journal of Experimental Medicine, vol. 207, no. 6, pp. 1135-1143, 2010.
121. G. R. Burmester, M. E. Weinblatt, I. B. McInnes et al., "Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 72, no. 9, pp. 1445-1452, 2013.
122. F. Behrens, P. P. Tak, M. Østergaard et al., "MOR103, a human monoclonal antibody to granulocyte-macrophage colonystimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial," Annals of the Rheumatic Diseases, 2014.
123. J. F. Seymour and J. J. Presneill, "Pulmonary alveolar proteinosis: progress in the first 44 years," American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 215-235, 2002.
124. B. C. Trapnell, J. A. Whitsett, and K. Nakata, "Pulmonary alveolar proteinosis,"The New England Journal ofMedicine, vol. 349, no. 26, pp. 2527-2539, 2003.
125. B. Carey and B. C. Trapnell, "Themolecular basis of pulmonary alveolar proteinosis," Clinical Immunology, vol. 135, no. 2, pp. 223-235, 2010.
126. G. Dranoff, A. D. Crawford, M. Sadelain et al., "Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis," Science, vol. 264, no. 5159, pp. 713-716, 1994.
127. B. C. Trapnell and J.A. Whitsett, "GM-CSFregulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense," Annual Review of Physiology, vol. 64, pp. 775-802, 2002.
128. M. Luisetti, G. Rodi, C. Perotti et al., "Plasmapheresis for treatment of pulmonary alveolar proteinosis," European Respiratory Journal, vol. 33, no. 5, pp. 1220-1222, 2009.
129. R. Tazawa, B. C. Trapnell, Y. Inoue et al., "Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis," American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 12, pp. 1345-1354, 2010.
130. S. B. Venkateshiah, T. D. Yan, T. L. Bonfield et al., "An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis," Chest, vol. 130, no. 1, pp. 227-237, 2006.
131. M. S. Kavuru, A. Malur, I. Marshall et al., "An open-label trial of rituximab therapy in pulmonary alveolar proteinosis," European Respiratory Journal, vol. 38, no. 6, pp. 1361-1367, 2011.
132. A. Malur, M. S. Kavuru, I. Marshall et al., "Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis," Respiratory Research, vol. 13, article 46, 2012.
133. T. J. Gross and G. W. Hunninghake, "Idiopathic pulmonary fibrosis," The New England Journal of Medicine, vol. 345, no. 7, pp. 517-525, 2001.
134. T. E. King Jr., A. Pardo, and M. Selman, "Idiopathic pulmonary fibrosis," The Lancet, vol. 378, no. 9807, pp. 1949-1961, 2011.
135. L. M. Crosby and C. M. Waters, "Epithelial repair mechanisms in the lung," American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 298, no. 6, pp. L715-L731, 2010.
136. J. G. N. Garcia, N. Parhami, D. Killam, P. L. Garcia, and B. A. Keogh, "Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis," The American Review of Respiratory Disease, vol. 133, no. 3, pp. 450-454, 1986.
137. J. G.N. Garcia, H. L. James, S. Zinkgraf, M. B. Perlman, and B. A. Keogh, "Lower respiratory tract abnormalities in rheumatoid interstitial lung disease. Potential role of neutrophils in lung injury," American Review of Respiratory Disease, vol. 136, no. 4, pp. 811-817, 1987.
138. E. S. White, M. H. Lazar, and V. J. Thannickal, "Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis," Journal of Pathology, vol. 201, no. 3, pp. 343-354, 2003.
139. Y. Shimizu, H. Kuwabara, A. Ono et al., "Intracellular Th1/Th2 balance of pulmonary CD4+ T cells in patients with active interstitial pneumonia evaluated by serumKL-6," Immunopharmacology and Immunotoxicology, vol. 28, no. 2, pp. 295-304, 2006.
140. P. Pignatti, G. Brunetti, D. Moretto et al., "Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis," The American Journal of Respiratory and Critical CareMedicine, vol. 173, no. 3, pp. 310-317, 2006.
141. J. Knobloch, H. Peters, D. Jungck, K. Müller, J. Strauch, and A. Koch, "TNFα-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism," Thorax, vol. 64, no. 12, pp. 1044-1052, 2009.
142. H. Taniguchi, S. Katoh, J. Kadota et al., "Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease," European Respiratory Journal, vol. 16, no. 5, pp. 959-964, 2000.
143. C. Walker, W. Bauer, R. K. Braun et al., "Activated T cells and cytokines in bronchoalveolar lavages frompatients with various lung diseases associated with eosinophilia," American Journal of Respiratory and Critical CareMedicine, vol. 150, no. 4, pp. 1038-1048, 1994.
144. Z. Xing, T. Braciak, Y. Ohkawara et al., "Gene transfer for cytokine functional studies in the lung: themultifunctional role of GM-CSF in pulmonary inflammation," Journal of Leukocyte Biology, vol. 59, no. 4, pp. 481-488, 1996.
145. Z. Xing, Y. Ohkawara, M. Jordana, F. L. Graham, and J. Gauldie, "Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions,"The Journal of Clinical Investigation, vol. 97, no. 4, pp. 1102-1110, 1996.
146. G. R. Johnson, T. J. Gonda, D. Metcalf, I. K. Kariharan, and S. Cory, "A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor," The EMBO Journal, vol. 8, no. 2, pp. 441-448, 1989.
147. S. Worgall, R. Singh, P. L. Leopold et al., "Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA," Blood, vol. 93, no. 2, pp. 655-666, 1999.
148. R. Vij and M. E. Strek, "Diagnosis and treatment of connective tissue disease-associated interstitial lung disease," Chest, vol. 143, no. 3, pp. 814-824, 2013.
149. A. de Lauretis, S. Veeraraghavan, and E. Renzoni, "Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?" Chronic Respiratory Disease, vol. 8, no. 1, pp. 53-82, 2011.
150. N. Sakaguchi, T. Takahashi, H. Hata et al., "Altered thymic Tcell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice," Nature, vol. 426, no. 6965, pp. 454-460, 2003.
151. R. C. Keith, J. L. Powers, E. F. Redente et al., "A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice," Experimental Lung Research, vol. 38, no. 2, pp. 55-66, 2012.
152. B. Khor, A. Gardet, and R. J. Xavier, "Genetics and pathogenesis of inflammatory bowel disease," Nature, vol. 474, no. 7351, pp. 307-317, 2011.
153. J. K. Yamamoto-Furusho and J. R. Korzenik, "Crohn's disease: innate immunodeficiency?" World Journal of Gastroenterology, vol. 12, no. 42, pp. 6751-6755, 2006.
154. J. R. Korzenik, "Is Crohn's disease due to defective immunity?" Gut, vol. 56, no. 1, pp. 2-5, 2007.
155. E. Bernasconi, L. Favre, M. H. Maillard et al., "Granulocytemacrophage colony-stimulating factor elicits bone marrowderived cells that promote efficient colonic mucosal healing," Inflammatory Bowel Diseases, vol. 16, no. 3, pp. 428-441, 2010.
156. J. Däbritz, "Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease," American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 306, no. 6, pp. G455-G465, 2014.
157. R. Gennari, J. W. Alexander, L. Gianotti, T. Eaves-Pyles, and S. Hartmann, "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance," Annals of Surgery, vol. 220, no. 1, pp. 68-76, 1994.
158. X. Han, K. Uchida, I. Jurickova et al., "Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease," Gastroenterology, vol. 136, no. 4, pp. e1261-e1263, 2009.
159. Y. Xu, N. H. Hunt, and S. Bao, "The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation," Cell Research, vol. 18, no. 12, pp. 1220-1229, 2008.
160. L. Egea, Y. Hirata, and M. F. Kagnoff, "GM-CSF: a role in immune and inflammatory reactions in the intestine," Expert Review of Gastroenterology and Hepatology, vol. 4, no. 6, pp. 723-731, 2010.
161. S. K. Sainathan, E. M. Hanna, Q. Gong et al., "Granulocyte macrophage colony-stimulating factor ameliorates DSSinduced experimental colitis," Inflammatory BowelDiseases, vol. 14, no. 1, pp. 88-99, 2008.
162. M. Biondo, Z. Nasa, A. Marshall, B. H. Toh, and F. Alderuccio, "Local transgenic expression of granulocyte macrophagecolony stimulating factor initiates autoimmunity," Journal of Immunology, vol. 166, no. 3, pp. 2090-2099, 2001.
163. D. Spight, B. Trapnell, B. Zhao, P. Berclaz, and T. P. Shanley, "Granulocyte-macrophage-colony-stimulating factordependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice," Shock, vol. 30, no. 4, pp. 434-442, 2008.
164. S. Sainathan, K. Bishnupuri, C. Houchen, S. Anant, and B. K. Dieckgraefe, Gm-Csf Increases Resistance to Apoptotic Cell Death and Enhances Crypt StemCell Survival in a Radiation- Induced Intestinal Injury Model, American Gastroenterological Association, Washington, DC, USA, 2005.
165. B. K. Dieckgraefe and J. R. Korzenik, "Treatment of active Crohn's disease with recombinant human granulocytemacrophage colony-stimulating factor," The Lancet, vol. 360, no. 9344, pp. 1478-1480, 2002.
166. J. R. Korzenik, B. K. Dieckgraefe, J. F. Valentine, D. F. Hausman, and M. J. Gilbert, "Sargramostim for active Crohn's disease,"The New England Journal ofMedicine, vol. 352, no. 21, pp. 2193-2201, 2005.
167. J. F. Valentine, R. N. Fedorak, B. Feagan et al., "Steroid-sparing properties of sargramostim in patients with corticosteroiddependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study," Gut, vol. 58, no. 10, pp. 1354-1362, 2009.
168. L. Roth, J. K. MacDonald, J. W. D. McDonald, and N. Chande, "Sargramostim(GM-CSF) for induction of remission in crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic reviewof randomized trials," Inflammatory Bowel Diseases, vol. 18, no. 7, pp. 1333-1339, 2012.
169. E. C. Cates, R. Fattouh, J. Wattie et al., "Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism," The Journal of Immunology, vol. 173, no. 10, pp. 6384-6392, 2004.
170. M. A. M. Willart, K. Deswarte, P. Pouliot et al., "Interleukin- 1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33," The Journal of Experimental Medicine, vol. 209, no. 8, pp. 1505-1517, 2012.
171. K. T. Nouri-Aria, K. Masuyama, M. R. Jacobson et al., "Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid," International Archives of Allergy and Immunology, vol. 117, no. 4, pp. 248-254, 1998.
172. N. Yamashita, H. Tashimo, H. Ishida et al., "Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF)," Cellular Immunology, vol. 219, no. 2, pp. 92-97, 2002.
173. R. Vlahos, S. Bozinovski, J. A. Hamilton, and G. P. Anderson, "Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage- colony stimulating factor (GM-CSF)," Pharmacology and Therapeutics, vol. 112, no. 1, pp. 106-115, 2006.
174. G.-R. Burmester, E. Feist, M. A. Sleeman, B. Wang, B. White, and F. Magrini, "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study," Annals of the RheumaticDiseases, vol. 70, no. 9, pp. 1542-1549, 2011.